Literature DB >> 9407116

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.

M Warmuth1, M Bergmann, A Priess, K Häuslmann, B Emmerich, M Hallek.   

Abstract

bcr-abl, the oncogene causing chronic myeloid leukemia, encodes a fusion protein with constitutively active tyrosine kinase and transforming capacity in hematopoietic cells. Various intracellular signaling intermediates become activated and/or associate by/with Bcr-Abl, including the Src family kinase Hck. To elucidate some of the structural requirements and functional consequences of the association of Bcr-Abl with Hck, their interaction was investigated in transiently transfected COS7 cells. Neither the complex formation of Hck kinase with Bcr-Abl nor the activation of Hck by Bcr-Abl was dependent on the Abl kinase activity. Both inactivating point mutations of Hck and dephosphorylation of Hck enhanced its complex formation with Bcr-Abl, indicating that their physical interaction was negatively regulated by Hck (auto)phosphorylation. Finally, experiments with a series of kinase negative Bcr-Abl mutants showed that Hck phosphorylated Bcr-Abl and induced the binding of Grb2 to Tyr177 of Bcr-Abl. Taken together, our results suggest that Bcr-Abl preferentially binds inactive forms of Hck by an Abl kinase-independent mechanism. This physical interaction stimulates the Hck tyrosine kinase, which may then phosphorylate the Grb2-binding site in Bcr-Abl.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407116     DOI: 10.1074/jbc.272.52.33260

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.

Authors:  Teodora Pene-Dumitrescu; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 2.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

Review 3.  Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Authors:  N Misaghian; G Ligresti; L S Steelman; F E Bertrand; J Bäsecke; M Libra; F Nicoletti; F Stivala; M Milella; A Tafuri; M Cervello; A M Martelli; J A McCubrey
Journal:  Leukemia       Date:  2008-09-18       Impact factor: 11.528

4.  The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

Authors:  Agata Klejman; Steven J Schreiner; Malgorzata Nieborowska-Skorska; Artur Slupianek; Matthew Wilson; Thomas E Smithgall; Tomasz Skorski
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

5.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

6.  PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Authors:  Nicholas C Wolff; Darren R Veach; William P Tong; William G Bornmann; Bayard Clarkson; Robert L Ilaria
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

7.  Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.

Authors:  Noriko Doki; Jiro Kitaura; Tomoyuki Uchida; Daichi Inoue; Yuki Kagiyama; Katsuhiro Togami; Masamichi Isobe; Shinichi Ito; Akie Maehara; Kumi Izawa; Naoko Kato; Toshihiko Oki; Yuka Harada; Fumio Nakahara; Hironori Harada; Toshio Kitamura
Journal:  Int J Hematol       Date:  2011-12-22       Impact factor: 2.490

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

Review 9.  Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.

Authors:  Haojian Zhang; Shaoguang Li
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

10.  Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry.

Authors:  John R Engen; Thomas E Wales; Shugui Chen; Elaine M Marzluff; Kerry M Hassell; David D Weis; Thomas E Smithgall
Journal:  Int Rev Phys Chem       Date:  2013-01-01       Impact factor: 4.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.